The US Food and Drug Administration (FDA) has granted clearance for Sensei Biotherapeutics’ investigational new drug (IND) application for SNS-101 enabling the initiation of a Phase I/II clinical trial to treat solid tumours.
The efficacy of SNS-101 as both a monotherapy and along with Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) will be assessed in the study.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics properties of SNS-101.
Patients will be administered an intravenous infusion of SNS-101 once every three weeks.
Sensei Biotherapeutics president and CEO John Celebi said: “Receiving IND clearance to advance our first conditionally active antibody into a Phase 1/2 clinical trial represents an important milestone for Sensei.
“We believe that SNS-101 has the potential to make a significant impact in the field and to improve the lives of cancer patients worldwide.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We are delighted to bring SNS-101 into the clinic and explore its potential as a transformative treatment option for patients with solid tumours.”
The first patient of the Phase I/II study is expected to be dosed in the middle of this year.
The study’s Phase I dose escalation part will be followed by an expansion Phase II in selected patients on determining a recommended dose for Phase II .
SNS-101, a conditionally active, human monoclonal IgG1 antibody, selectively blocks the VISTA checkpoint in the tumour microenvironment.
